ImpediMed

Born from a vision to revolutionize medical technology, ImpediMed's journey began in Brisbane, Australia, in 1999. Founded by Melvyn and Lucille Bridges, the company was established with a clear mission: to develop and distribute innovative medical devices that leverage the power of bioimpedance spectroscopy (BIS). This technology held the promise of non-invasively assessing and monitoring the intricate fluid status and tissue composition within the human body, opening new frontiers in patient care. From its inception, ImpediMed was driven by a commitment to address unmet clinical needs, initially focusing on the development of devices that could provide crucial data for a variety of medical applications. As a publicly listed company on the Australian Stock Exchange (ASX: IPD), it embarked on a path of rigorous research and development, steadily building a foundation of scientific evidence and clinical validation for its technology.

A pivotal moment in ImpediMed's story was the strategic decision to concentrate its efforts on one of the most challenging and often overlooked consequences of cancer treatment: secondary lymphedema. Recognizing the profound impact this chronic condition has on patients' quality of life, particularly for breast cancer survivors, the company dedicated itself to creating a solution for early detection and prevention. This led to the development of their flagship product, the SOZO® Digital Health Platform. This platform, featuring the proprietary L-Dex® technology, represented a significant leap forward. It provided clinicians with the ability to detect subtle, subclinical fluid changes before the physical symptoms of lymphedema manifest, enabling timely intervention and potentially preventing the condition from becoming a lifelong burden. Today, with operations spanning the United States and Europe, ImpediMed continues its journey, driven by the vision to leave no patient who could benefit from their technology untested and to forge new standards of care in oncology, heart failure, and beyond.